Fortis Healthcare Ltd. (IN:FORTIS)
:FORTIS
Top Page
Fortis Healthcare Ltd.
(FORTIS)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹886.00
▼(-3.16% Downside)
Action:ReiteratedDate:11/15/25
Fortis Healthcare Ltd. has a strong financial foundation, which is the most significant factor in its overall score. However, technical analysis indicates bearish momentum, and the high P/E ratio suggests overvaluation, both of which weigh down the overall score. The absence of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Revenue Growth
Sustained ~16% revenue growth reflects expanding patient volumes and service penetration across Fortis’ hospital network. Over 2–6 months this trend supports scale benefits, better fixed-cost absorption and reinvestment capacity into facilities and specialties, strengthening durable top-line momentum.
Negative Factors
Capex Volatility
Variable capital spending creates unpredictability in free cash flow timing and magnitude, complicating long-term planning for an asset-heavy hospital network. Over 2–6 months, uneven capex can pressure liquidity and delay returns on expansion projects or refurbishment programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained ~16% revenue growth reflects expanding patient volumes and service penetration across Fortis’ hospital network. Over 2–6 months this trend supports scale benefits, better fixed-cost absorption and reinvestment capacity into facilities and specialties, strengthening durable top-line momentum.
Read all positive factors
Fortis Healthcare Ltd. (FORTIS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹634.32B
Dividend Yield0.11%
Average Volume (3M)66.29K
Price to Earnings (P/E)86.1
Beta (1Y)1.09
Revenue Growth15.33%
EPS Growth54.62%
CountryIN
Employees12,088
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)3.18
Shares Outstanding754,958,100
10 Day Avg. Volume118,360
30 Day Avg. Volume66,292
Financial Highlights & Ratios
PEG Ratio2.28
Price to Book (P/B)5.83
Price to Sales (P/S)6.67
P/FCF Ratio90.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,044.00Price Target Upside14.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)19.01
Revenue Forecast (FY)₹107.51B
Fortis Healthcare Ltd. Business Overview & Revenue Model
Company Description
Fortis Healthcare Limited, an integrated healthcare delivery service provider, offers secondary, tertiary, and quaternary care in India, the United Arab Emirates, Sri Lanka, and internationally. Its healthcare verticals comprise hospitals, diagnos...
How the Company Makes Money
Fortis Healthcare primarily generates revenue from providing healthcare services through its hospital network. Key revenue streams typically include (1) inpatient services (room charges, nursing, ICU, inpatient procedures and surgeries), (2) outpa...
Fortis Healthcare Ltd. Financial Statement Overview
Summary
Income Statement
81
Very Positive
Balance Sheet
76
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 84.34B | 77.86B | 68.97B | 62.98B | 57.18B | 40.30B |
| Gross Profit | 36.84B | 45.86B | 39.73B | 23.08B | 32.25B | 20.72B |
| EBITDA | 18.18B | 15.00B | 11.87B | 10.37B | 9.96B | 3.47B |
| Net Income | 10.14B | 7.74B | 5.99B | 5.89B | 5.55B | -1.10B |
Balance Sheet | ||||||
| Total Assets | 150.13B | 136.92B | 132.89B | 124.34B | 118.85B | 111.55B |
| Cash, Cash Equivalents and Short-Term Investments | 4.48B | 5.08B | 6.00B | 3.66B | 4.13B | 4.16B |
| Total Debt | 31.95B | 24.75B | 11.55B | 9.26B | 12.55B | 15.31B |
| Total Liabilities | 53.20B | 45.22B | 47.33B | 43.33B | 48.76B | 44.37B |
| Stockholders Equity | 94.29B | 89.17B | 76.63B | 72.42B | 61.78B | 61.20B |
Cash Flow | ||||||
| Free Cash Flow | 800.30M | 5.77B | 1.58B | 3.75B | 6.50B | 2.67B |
| Operating Cash Flow | 6.76B | 14.24B | 11.00B | 8.22B | 8.65B | 4.85B |
| Investing Cash Flow | -9.86B | -7.79B | -8.86B | -3.74B | -5.14B | -1.35B |
| Financing Cash Flow | 2.46B | -7.14B | -864.58M | -4.71B | -5.17B | -1.43B |
Fortis Healthcare Ltd. Technical Analysis
Neutral
914.95
Price Trends
867.33
Negative
887.08
Negative
902.10
Negative
Market Momentum
-21.27
Negative
49.53
Neutral
63.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FORTIS, the sentiment is Neutral. The current price of 914.95 is above the 20-day moving average (MA) of 831.44, above the 50-day MA of 867.33, and above the 200-day MA of 902.10, indicating a neutral trend. The MACD of -21.27 indicates Negative momentum. The RSI at 49.53 is Neutral, neither overbought nor oversold. The STOCH value of 63.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:FORTIS.
Fortis Healthcare Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹347.20B | 75.82 | ― | 0.24% | 14.72% | 8.37% | |
66 Neutral | ₹1.05T | 50.39 | ― | 0.27% | 13.66% | 41.32% | |
66 Neutral | ₹228.85B | 68.44 | ― | 0.89% | 10.80% | 32.79% | |
61 Neutral | ₹634.32B | 86.12 | ― | 0.11% | 15.33% | 54.62% | |
61 Neutral | ₹90.26B | 60.35 | ― | 0.21% | 15.41% | 5.93% | |
59 Neutral | ₹842.31B | 55.46 | ― | 0.04% | 23.22% | -19.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:FORTIS
Fortis Healthcare Ltd.
840.20
187.12
28.65%
IN:APOLLOHOSP
Apollo Hospitals Enterprise Limited
7,322.20
506.59
7.43%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,365.80
43.91
3.32%
IN:MANKIND
Mankind Pharma Ltd.
2,040.35
-272.99
-11.80%
IN:METROPOLIS
Metropolis Healthcare Ltd.
435.35
41.33
10.49%
IN:NH
Narayana Hrudayalaya Ltd.
1,698.95
13.12
0.78%
Fortis Healthcare Ltd. Corporate Events
Fortis Healthcare Wins Shareholder Nod for Group-Wide ESOP 2026
Mar 18, 2026
Fortis Healthcare Ltd. shareholders have approved a new employee stock option scheme, ESOS 2026, through a postal ballot conducted via e-voting in line with regulatory requirements. The scheme covers eligible employees not only of Fortis Healthcar...
Fortis Healthcare Shareholders Approve Group-Wide ESOP 2026 Scheme
Mar 18, 2026
Fortis Healthcare Ltd. shareholders have approved the Fortis Healthcare Limited Employees Stock Option Scheme 2026 through a postal ballot conducted via e-voting. The scheme covers grants of stock options not only to eligible employees of the pare...
Fortis Healthcare Reports No Requests Under SEBI Physical Share Transfer Window
Mar 16, 2026
Fortis Healthcare has informed the stock exchanges about the status of a special window for re-lodgement of transfer requests for physical shares, as mandated by recent SEBI circulars. The company disclosed a report from its Registrar and Share Tr...
Fortis Healthcare Completes Merger of Key Subsidiaries into Fortis Hospitals
Mar 1, 2026
Fortis Healthcare has announced that its composite scheme of merger by absorption involving several wholly owned subsidiaries has become effective following regulatory filings. The company filed certified orders from the National Company Law Tribu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.